Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study
Alemtuzumab was feasible to administer in adults with ALL receiving intensive chemotherapy, but was without evidence of benefit.
Authors
- Wendy Stock (ORCID: https://orcid.org/0000-0002-8349-9200)
- Oudom Kour
- Gerard Lozanski (ORCID: https://orcid.org/0000-0002-5095-0456)
- Gregory Malnassy (ORCID: https://orcid.org/0000-0003-4794-7210)
- David L. Grinblatt (ORCID: https://orcid.org/0000-0002-2118-0042)
- Marlise Rachael Luskin (ORCID: https://orcid.org/0000-0002-5781-4529)
- Ravi Vij (ORCID: https://orcid.org/0000-0001-8795-3610)
- Eunice S. Wang (ORCID: https://orcid.org/0000-0002-8644-0968)
- Betsy LaPlant
- Spero R. Cataland (ORCID: https://orcid.org/0000-0001-8977-6910)
- Jonathan E. Kolitz (ORCID: https://orcid.org/0000-0003-2700-4784)
- Richard M. Stone (ORCID: https://orcid.org/0000-0002-7526-2633)
- Richard A. Larson (ORCID: https://orcid.org/0000-0001-9168-3203)
- Krzysztof Mrózek (ORCID: https://orcid.org/0000-0002-1408-5063)
- Noreen Fulton
- Emily Curran (ORCID: https://orcid.org/0000-0001-8159-4733)
- Geoffrey L. Uy (ORCID: https://orcid.org/0000-0002-7809-0996)
- Jun Yin (ORCID: https://orcid.org/0000-0003-3242-9664)
- Bayard L. Powell
- C. D. Bloomfield
Institutions
- Atrium Health Wake Forest Baptist (US)
- Roswell Park Comprehensive Cancer Center (US)
- Northwell Health (US)
- Mayo Clinic (US)
- NorthShore University HealthSystem (US)
- Washington University in St. Louis (US)
- The Ohio State University Wexner Medical Center (US)
- Moffitt Cancer Center (US)
- University of Chicago (US)
- Dana-Farber Cancer Institute (US)
- Evanston Hospital (US)
- Wake Forest Baptist Comprehensive Cancer Center
- The Ohio State University (US)
- University of Cincinnati (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1002/cncr.35750
- Citations
- 2
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 3.76
Funders
- Bayer
- National Institutes of Health
- Sanofi Genzyme
- National Cancer Institute